ConSynance Joins the Prader-Willi Syndrome Clinical Trial Consortium
March 11, 2019 09:00 ET
|
ConSynance Therapeutics, Inc.
Rensselaer, New York., March 11, 2019 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc., a clinical-stage biotechnology company developing two innovative treatments for Prader-Willi Syndrome (PWS),...
INmune Bio Co-Founders to Present at World Immunotherapy Congress during the Festival of Biologics San Diego
February 26, 2019 09:30 ET
|
INmune Bio, Inc.
Presentations to address the role of the innate immune system in treating cancer LA JOLLA, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused...
INmune Bio Awarded a $1 Million Grant for the Development of XPro1595 for the treatment of Alzheimer’s Disease
February 11, 2019 08:00 ET
|
INmune Bio, Inc.
The Alzheimer’s Association awarded INmune Bio the Part the Cloud to RESCUE grant to target neuroinflammation in Alzheimer’s Disease LA JOLLA, Calif., Feb. 11, 2019 (GLOBE NEWSWIRE) -- INmune...
INmune Bio, Inc. Announces Pricing of Initial Public Offering
January 15, 2019 15:00 ET
|
INmune Bio, Inc.
LA JOLLA, CA, Jan. 15, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (“INmune” or the “Company”), an immunotherapy company focused on developing therapies that harness the patient’s innate immune...
INmune Bio Granted Phase I Clinical Trial Authorization of Lead Product INKmune™ in Refractory and Recurrent Ovarian Cancer Patients
December 19, 2018 08:00 ET
|
INmune Bio, Inc.
LA JOLLA, California, Dec. 19, 2018 (GLOBE NEWSWIRE) -- INmune Bio Inc., an immunotherapy company developing treatments to reprogram the innate immune system to fight disease, announced today that...
Trastuzumab-Resistant HER2 Positive Breast Cancer Reversed By Treatment with INB03
December 11, 2018 08:30 ET
|
INmune Bio, Inc.
Study Results Presented at San Antonio Breast Cancer Symposium 2018 LA JOLLA, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunotherapy company developing treatments to...
INmune Bio Announces Publication of Myeloid-Derived Suppressor Cells (MDSC) Report in the Cell’s Trends in Pharmacological Sciences Journal
December 07, 2018 09:00 ET
|
INmune Bio, Inc.
Manuscript highlights the vital role of MDSC in the tumor microenvironment (TME) LA JOLLA, Calif.,, Dec. 07, 2018 (GLOBE NEWSWIRE) -- INmune Bio Inc., an immunotherapy company developing...
INmune Nominated for Buzz of Bio Award at 2019 CEO & Investor Conference
December 04, 2018 08:30 ET
|
INmune Bio, Inc.
-Voting begins today: Click here to cast your vote- LA JOLLA, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunotherapy company focused on developing therapies that harness...
University of Tennessee Haslam College of Business Recognizes Provectus Biopharmaceuticals Chairman Ed Pershing as 2018 Outstanding Entrepreneur
November 12, 2018 09:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that Ed Pershing, CPA, the Chairman of the Company’s board of directors, was recognized by the Haslam...
PROVECTUS ANNOUNCES PRESENTATION OF UPDATED RESULTS FROM PHASE 1B TRIAL OF PV-10 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR TREATMENT OF ADVANCED MELANOMA AT SMR 2018 CONGRESS
October 25, 2018 08:00 ET
|
Provectus Biopharmaceuticals Inc.
- Single-agent adverse effect profiles of PV-10 and Keytruda were maintained - 65% overall objective response rate with 9% complete response, via RECIST 1.1 KNOXVILLE, TN, Oct. 25, 2018 ...